Results of asciminib therapy as part of managed access program in patients with chronic myeloid leukemia with T315I mutation

Results of asciminib therapy as part of managed access program in patients with chronic myeloid leukemia with T315I mutation

Background. The most common mechanism of resistance to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML) is point mutations in the BCR::ABL1 gene. Of particular importance is the T315I mutation, which causes insensitivity of leukemia cells to all ATp-competitive...

Full description

Saved in:
Bibliographic Details
Main Authors: A. N. Petrova, E. G. Lomaia, E. V. Morozova, O. A. Shukhov, E. Yu. Chelysheva, Yu. Yu. Vlasova, E. A. Kuzmina, O. V. Kulemina, I. S. Nemchenko, A. V. Bykova, A. B. Sudarikov, A. V. Kokhno, A. G. Turkina
Format: Article
Language:Russian
Published: ABV-press 2025-05-01
Series:Онкогематология
Subjects:
chronic myeloid leukemia
t315i mutation
asciminib
additional chromosomal abnormalities
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/1029
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items